- Home
- AMGN vs DE Comparison
AMGN vs DE Comparison
Compare AMGN & DE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AMGN
- DE
- Stock Information
- Founded
- AMGN 1980
- DE 1837
- Country
- AMGN United States
- DE United States
- Employees
- AMGN N/A
- DE N/A
- Industry
- AMGN Biotechnology: Biological Products (No Diagnostic Substances)
- DE Industrial Machinery/Components
- Sector
- AMGN Health Care
- DE Industrials
- Exchange
- AMGN Nasdaq
- DE Nasdaq
- Market Cap
- AMGN 156.2B
- DE 133.0B
- IPO Year
- AMGN N/A
- DE N/A
- Fundamental
- Price
- AMGN $288.18
- DE $506.24
- Analyst Decision
- AMGN Buy
- DE Buy
- Analyst Count
- AMGN 21
- DE 15
- Target Price
- AMGN $323.62
- DE $515.53
- AVG Volume (30 Days)
- AMGN 3.2M
- DE 1.3M
- Earning Date
- AMGN 05-01-2025
- DE 05-15-2025
- Dividend Yield
- AMGN 3.30%
- DE 1.28%
- EPS Growth
- AMGN 56.16
- DE N/A
- EPS
- AMGN 10.94
- DE 20.67
- Revenue
- AMGN $34,126,000,000.00
- DE $45,384,000,000.00
- Revenue This Year
- AMGN $7.62
- DE N/A
- Revenue Next Year
- AMGN $1.88
- DE $6.87
- P/E Ratio
- AMGN $26.34
- DE $24.49
- Revenue Growth
- AMGN 15.56
- DE N/A
- 52 Week Low
- AMGN $253.30
- DE $340.20
- 52 Week High
- AMGN $346.85
- DE $533.78
- Technical
- Relative Strength Index (RSI)
- AMGN 58.41
- DE 56.68
- Support Level
- AMGN $269.10
- DE $502.08
- Resistance Level
- AMGN $276.90
- DE $533.78
- Average True Range (ATR)
- AMGN 5.90
- DE 10.77
- MACD
- AMGN 2.48
- DE -1.88
- Stochastic Oscillator
- AMGN 97.70
- DE 32.52
About AMGN Amgen Inc.
Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
About DE Deere & Company
Deere is the world's leading manufacturer of agricultural equipment and a major producer of construction machinery. The company is divided into four reporting segments: production & precision agriculture (PPA), small agriculture & turf (SAT), construction & forestry (CF), and financial services (FS), its captive finance subsidiary. The core PPA business is the largest contributor to sales and profits by far. Geographically, Deere sales are 60% US/Canada, 17% Europe, 14% Latin America, and 9% rest of world. Deere goes to market through a robust dealer network that includes over 2,000 dealer locations in North America with reach into over 100 countries. John Deere financial provides retail financing for machinery to its customers and wholesale financing for dealers.